Investigating how EAG channels affect cancer and brain function
Functional mechanisms and therapeutic potential of EAG channel regulators
['FUNDING_R01'] · GEORGETOWN UNIVERSITY · NIH-11054658
This study is looking at how certain channels in brain cells, called EAG potassium channels, affect brain activity and cancer growth, with the hope of finding new treatments for conditions related to these channels.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | GEORGETOWN UNIVERSITY (nih funded) |
| Locations | 1 site (WASHINGTON, UNITED STATES) |
| Trial ID | NIH-11054658 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding the role of EAG potassium channels in regulating brain activity and cancer progression. The team will explore how these channels are influenced by specific intracellular ligands, which could lead to new therapeutic approaches for conditions linked to EAG channel dysfunction. By using advanced techniques like X-ray crystallography and computational simulations, they aim to uncover the structural mechanisms of EAG channel regulation. Additionally, they will identify new ligands that can modulate EAG channel function and assess their potential therapeutic effects.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with neurological disorders or cancers associated with EAG channel dysfunction.
Not a fit: Patients with conditions unrelated to EAG channel function may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to novel treatments for neurological disorders and cancer by targeting EAG channels.
How similar studies have performed: While the specific approach of targeting EAG channels is relatively novel, similar research has shown promise in understanding ion channel regulation in other contexts.
Where this research is happening
WASHINGTON, UNITED STATES
- GEORGETOWN UNIVERSITY — WASHINGTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BRELIDZE, TINATIN I — GEORGETOWN UNIVERSITY
- Study coordinator: BRELIDZE, TINATIN I
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer therapy, Cancer cell line, cancer metastasis, cancer progression